REPLIGEN CORP
RGENNasdaq
$147.25
↓ -0.9%Jul 17 close · end-of-day
Price
1Y↑ +23.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$8.3B
Enterprise Value
$8.1B
P/E
161.8
P/S
10.9
P/B
4.0
EV/EBITDA
56.2
PEG
—
FCF Yield
1.3%
Dividend Yield
—
Revenue (TTM)
$763.3M
Net Income (TTM)
$51.4M
Free Cash Flow (TTM)
$106.0M
Gross Margin
—
Operating Margin
8.5%
Net Margin
6.7%
ROE
2.4%
ROIC
3.2%
Debt / Equity
0.3
Net Cash
$237.9M
Return 1Y
+18.7%
Company profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company sells its products to life sciences, biopharmaceutical companies; laboratory researchers; and contract manufacturing organizations.
- CEO
- Tony J. Hunt
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2,020
- Headquarters
- Massachusetts
- Website
- repligen.com
Management & directors
- Garland Jason KCFO
- Douglass Brian RobbCHIEF PRODUCT OFFICER
- Loeillot OlivierChief Executive Officer
- Bylund JamesChief Operating Officer
- Kuriyel RalfSenior VP, R&D
- Hughes ViolettaCHIEF ACCOUNTING OFFICER
Roles derived from SEC Form 4 filings.
Earnings
RGEN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$194.3M↑ +14.8%
Diluted EPS$0.15↑ +50.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $366.3M | $670.5M | $801.5M | $632.4M | $634.4M | $738.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $69.8M | $167.2M | $224.7M | $47.7M | -$35.1M | $55.2M |
| Net income | $59.9M | $128.3M | $186.0M | $35.6M | -$25.5M | $48.9M |
| Diluted EPS | $1.11 | $2.24 | $3.24 | $0.63 | -$0.46 | $0.86 |
| Operating cash flow | $62.6M | $119.0M | $172.1M | $113.9M | $175.4M | $117.4M |
| Free cash flow | $40.2M | $51.9M | $87.2M | $77.7M | $149.7M | $93.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 19.1% | 24.9% | 28.0% | 7.5% | -5.5% | 7.5% |
| Net margin | 16.4% | 19.1% | 23.2% | 5.6% | -4.0% | 6.6% |
| Line item | Q '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $154.9M | $167.5M | $169.2M | $182.4M | $188.8M | $197.9M | $194.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | -$7.8M | -$36.5M | $6.6M | $13.9M | $16.8M | $17.9M | $15.9M |
| Net income | — | -$654,000.00 | -$33.9M | $5.8M | $14.9M | $14.9M | $13.3M | $8.3M |
| Diluted EPS | — | -$0.01 | -$0.61 | $0.10 | $0.26 | $0.26 | $0.24 | $0.15 |
| Operating cash flow | — | $49.3M | $39.2M | $15.0M | $28.6M | $48.1M | $25.7M | $28.3M |
| Free cash flow | — | $42.3M | $33.6M | $11.4M | $21.5M | $43.4M | $17.6M | $23.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | -5.1% | -21.8% | 3.9% | 7.6% | 8.9% | 9.0% | 8.2% |
| Net margin | — | -0.4% | -20.2% | 3.4% | 8.2% | 7.9% | 6.7% | 4.3% |
Company news
Jul 17, 2026
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Garland Jason K· CFO | Sale | 530 | $150.00 | $79,500.00 | filing |
| 2026-06-25 | Garland Jason K· CFO | Sale | 733 | $145.00 | $106,285.00 | filing |
| 2026-05-14 | Madaus Martin D | Award | 995 | $0.00 | $0.00 | filing |
| 2026-05-14 | Konstantinov Konstantin | Award | 995 | $0.00 | $0.00 | filing |
| 2026-05-14 | Mhatre Rohin | Award | 995 | $0.00 | $0.00 | filing |
| 2026-05-14 | EGLINTON MANNER CARRIE | Award | 995 | $0.00 | $0.00 | filing |
| 2026-05-14 | Pax Margaret | Award | 995 | $0.00 | $0.00 | filing |
| 2026-05-14 | DAWES KAREN A | Award | 995 | $0.00 | $0.00 | filing |
| 2026-05-14 | MUIR GLENN P | Award | 995 | $0.00 | $0.00 | filing |
| 2026-05-14 | BARTHELEMY NICOLAS | Award | 995 | $0.00 | $0.00 | filing |
| 2026-05-07 | MUIR GLENN P | Option exercise | 2,434 | $38.76 | $94,341.84 | filing |
| 2026-05-07 | Douglass Brian Robb· CHIEF PRODUCT OFFICER | Tax withholding | 334 | $126.43 | $42,227.62 | filing |
| 2026-04-21 | Loeillot Olivier· Chief Executive Officer | Sale | 3,832 | $140.00 | $536,480.00 | filing |
| 2026-03-05 | KURIYEL RALF· Senior VP, R&D | Award | 5,284 | $0.00 | $0.00 | filing |
| 2026-03-05 | Loeillot Olivier· Chief Executive Officer | Award | 24,134 | $0.00 | $0.00 | filing |
| 2026-03-05 | Bylund James· Chief Operating Officer | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-03-05 | Garland Jason K· CFO | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-03-04 | Bylund James· Chief Operating Officer | Tax withholding | 62 | $125.84 | $7,802.08 | filing |
| 2026-03-04 | KURIYEL RALF· Senior VP, R&D | Tax withholding | 42 | $125.84 | $5,285.28 | filing |
| 2026-03-04 | Bylund James· Chief Operating Officer | Award | 125 | $0.00 | $0.00 | filing |
| 2026-03-04 | KURIYEL RALF· Senior VP, R&D | Award | 125 | $0.00 | $0.00 | filing |
| 2026-03-02 | Hunt Anthony | Tax withholding | 9,897 | $124.97 | $1.2M | filing |
| 2026-03-02 | Bylund James· Chief Operating Officer | Tax withholding | 2,433 | $124.97 | $304,052.01 | filing |
| 2026-03-02 | Loeillot Olivier· Chief Executive Officer | Tax withholding | 1,610 | $124.97 | $201,201.70 | filing |
| 2026-03-02 | KURIYEL RALF· Senior VP, R&D | Tax withholding | 923 | $124.97 | $115,347.31 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.